Suscribirse

Extracorporeal shock wave lithotripsy is a safe and effective treatment for pancreatic stones coexisting with pancreatic pseudocysts - 21/06/16

Doi : 10.1016/j.gie.2015.10.026 
Bai-Rong Li, MD , 1, 2, 3, Zhuan Liao, MD , 1, 2, Ting-Ting Du, MD , 1, Bo Ye, MD 1, 2, Hui Chen, MD 1, 2, Jun-Tao Ji, MD 1, Zhao-Hong Zheng, MD 1, Jun-Feng Hao, MD 1, Shou-Bin Ning, MD 3, Dan Wang, MD 1, 2, Jin-Huan Lin, MD 1, 2, Liang-Hao Hu, MD 1, 2, , Zhao-Shen Li, MD 1, 2,
1 Department of Gastroenterology, Changhai Hospital, The Second Military Medical University, Shanghai, China 
2 Digestive Endoscopy Center, Changhai Hospital, The Second Military Medical University, Shanghai, China 
3 Department of Gastroenterology, Air Force General Hospital, Beijing, China 

Reprint requests: Zhao-Shen Li, MD, or Liang-Hao Hu, MD, Department of Gastroenterology, Digestive Endoscopy Center, Changhai Hospital, The Second Military Medical University, 168 Changhai Road, Shanghai 200433, China.Department of Gastroenterology, Digestive Endoscopy Center, Changhai Hospital, The Second Military Medical University168 Changhai RoadShanghai 200433China

Abstract

Background and Aims

We aimed to investigate outcomes of pancreatic extracorporeal shock wave lithotripsy (P-ESWL) for the removal of large pancreatic stones coexisting with pancreatic pseudocysts (PPCs) in chronic pancreatitis (CP).

Methods

This is a prospective study performed in CP patients with at least 1 stone (≥5 mm). Patients were divided into the PPC group (stones coexisting with PPCs) or the control group (stones alone). Patients were initially subjected to successive P-ESWL treatments, followed by ERCP. Primary outcomes were P-ESWL adverse events, and secondary outcomes were stone clearance, long-term pain relief, improved quality-of-life scores, and PPC regression.

Results

A total of 849 patients (59 in the PPC group and 790 in the control group) was subjected to P-ESWL between March 2011 and October 2013. Occurrences of P-ESWL adverse events were similar between the PPC group and the control group (11.86% vs 12.41%, P = .940). After the treatment of initial P-ESWL combined with ERCP, the complete, partial, and nonclearance of stones occurred in 67.24%, 20.69%, and 12.07%, respectively, of patients in PPC group, with no significant difference from the control group (complete, partial, and nonclearance: 83.17%, 10.40%, and 11.39%, respectively; P = .106). Fifty-five of 59 patients (93.22%) with PPCs were followed for a median period of 21.9 months (range, 12.0-45.1). PPCs disappeared in 56.36% (31/55) and 76.36% (42/55) of patients after 3 months and 1 year of follow-up visits, respectively. Moreover, complete and partial pain relief were achieved in 63.64% (35/55) and 25.45% (14/55) of patients, respectively. The scores for quality of life (P < .001), physical health (P < .001), and weight loss (P < .001) improved.

Conclusions

In our multispecialty tertiary center, initial P-ESWL followed by ERCP was safe in patients with coexisting pancreatic stones and PPCs and effective for stone clearance, main pancreatic duct drainage, and pain relief.

El texto completo de este artículo está disponible en PDF.

Abbreviations : CP, SF-36, MPD, P-ESWL, PPC


Esquema


 DISCLOSURE: The following authors received research support for this study from the National Natural Science Foundation of China: Z. Liao (grant no. 81270541) and L.-H. Hu (grant nos. 81100316 and 81470883); from the Shanghai ChenGuang Program: L.-H. Hu (grant no. 12CG40); and from the Shanghai Rising Star Program: Z. Liao (grant no. 13QA1404600). All other authors disclosed no financial relationships relevant to this publication.
 If you would like to chat with an author of this article, you may contact Dr Li at zhaoshen-li@hotmail.com or Dr Hu at lianghao-hu@hotmail.com
 See CME section; p. 142.


© 2016  American Society for Gastrointestinal Endoscopy. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 84 - N° 1

P. 69-78 - juillet 2016 Regresar al número
Artículo precedente Artículo precedente
  • Ex vivo comparison of the lumen-apposing properties of EUS-specific stents (with video)
  • Anthony Yuen Teoh, Enders Kwok Ng, Shannon Melissa Chan, Mona Lai, Stuart Moran, Kenneth Frank Binmoeller, Jong Ho Moon, Khek Yu Ho
| Artículo siguiente Artículo siguiente
  • Extracorporeal shock wave lithotripsy: the cornerstone of pancreatic endotherapy
  • Suryaprakash Bhandari, Amit Maydeo

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.